[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,634,0,25,[9,41,62,89,110,130,152,171,181,204,230,248,272,298,327,338,361,378,398,425,445,469,493,514,533],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100054045","phase-1-a-clinical-trial-of-mk-4082-in-healthy-participants-mk-4082-005-100054045",false,"NCT07697625","A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)","A Clinical Study to Evaluate the Plasma Pharmacokinetics of a Single Dose of MK-4082 With and Without Diltiazem Coadministration in Healthy Participants","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is in good health\n* Body mass index (BMI) between 18 and 32 kg\u002Fm\\^2, inclusive\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history of previous surgical treatment for obesity that may induce malabsorption, history of bowel resection \\>20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure for weight loss\n* Had a recent pancreatitis or has a history of pancreatitis",true,"ALL","18 Years","55 Years",{"count":22,"type":23},18,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","Researchers are looking for new weight loss medicines for people with higher body weight. The trial medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a trial medicine to participants with a health condition, researchers first do trials in healthy participants to find a safe dose level (amount) of the trial medicine.\n\nThe goal of this study is to learn what happens to MK-4082 in a person's body over time. Researchers will compare what happens to levels of MK-4082 in people's blood when it is taken without (Period 1) and with (Period 2) another medicine called diltiazem. Researchers also want to learn about the safety of MK-4082 taken with and without diltiazem and if people tolerate them.",[29],"Healthy","NOT_YET_RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":33,"type":23},{"date":37,"type":23},"2026-09-28",{"name":39,"class":40},"Merck Sharp & Dohme LLC","INDUSTRY",{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":17,"sex":18,"minAge":48,"maxAge":20,"enrollmentInfo":49,"targetDuration":4,"studyType":24,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100053995","phase-1-a-clinical-study-of-mk-7262-and-enlicitide-in-healthy-participants-mk-7262-003-100053995","NCT07619443","A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)","A Clinical Drug-Drug Interaction Study to Evaluate the Mutual Pharmacokinetic Effects of MK-7262 and Enlicitide in Healthy Participants","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is in good health before randomization\n* Has a body mass index (BMI) ≥18 and ≤32 kg\u002Fm\\^2, inclusive\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history or presence of clinically significant medical or psychiatric condition or disease\n* Has a history of cancer","19 Years",{"count":50,"type":23},30,[26],"The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.",[29],"RECRUITING",{"date":33,"type":34},{"date":57,"type":34},"2026-07-01",{"date":59,"type":23},"2026-09-12",{"name":39,"class":40},1,{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":17,"sex":18,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":24,"phases":73,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":61},"100054007","phase-1-pet-imaging-of-phosphodiesterase-4-pde4-in-volunteers-with-alzheimer-disease-ad-or-mild-cognitive-impairment-mci-100054007","NCT07169630","PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)","PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)","* INCLUSION CRITERIA:\n\nParticipants will be referred by a physician with the suspected diagnosis of AD or MCI. However, the PI of this protocol will provide the final diagnosis. For this reason, this protocol will have just one consent form for participants suspected of having either AD or MCI.\n\nAD and MCI Study Groups:\n\nParticipants must meet all the following criteria:\n\n* Aged 50 or older.\n* Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n* Have been diagnosed by a neurologist or psychiatrist with MCI or AD.\n* Be in good general health as evidenced by medical history and physical examination.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nHealthy Volunteers:\n\nParticipants must meet all the following criteria:\n\n* Aged 50 or older.\n* Able to provide informed consent.\n* Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth the study groups will be excluded if they meet any of the following criteria:\n\n* Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n* Participants should not have taken non-steroidal anti-inflammatory drugs (NSAIDs) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n* Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n* Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n* Are unable to travel to the NIH.\n* Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n* Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the volunteer and\u002For caregiver during the screening visit.\n* Participants must not have substance use disorder or alcohol use disorder.\n* Participants should not be under treatment or previously treated with an amyloid antibody such as lecanemab.\n* Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n* Pregnancy or breast feeding.\n* HIV infection.\n* Non-English speaking participants.\n\nExclusion of Children:\n\nInclusion of children is not appropriate, because this protocol has more than minimal risk from radiation exposure without the possibility of direct benefit.\n\nExclusion of Pregnant or Breastfeeding Women:\n\nPregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will not require contraception for this protocol to allow participants autonomy in medical decision-making. However, while we will not require contraception for woman of childbearing potential, we will perform a pregnancy test at screening and prior to all procedures to ensure participants are not pregnant\n\nExclusion of Participants who are HIV Positive:\n\nPersons with HIV infection are excluded because HIV infection itself may change cAMP signaling.\n\nExclusion of Non-English-Speaking Participants:\n\nNon-English-speaking participants will be excluded from participation in this study because neuropsychological testing is required by this protocol. This testing, which is critical for interpreting study results, has not been validated in other languages or when using a translator.","50 Years","100 Years",{"count":72,"type":23},90,[26],"Background:\n\nAbout 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI.\n\nObjective:\n\nTo test whether medical imaging using a new radiotracer (\\[18F\\]PF-06445974) can measure PDE4B in the brains of people with AD or MCI.\n\nEligibility:\n\nPeople aged 50 years and older with AD or MCI. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have up to 5 clinic visits with 3 imaging scans of the brain.\n\nThey will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory.\n\nParticipants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each.\n\nParticipants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....",[76,77,29],"Alzheimer s Disease","Mild Cognitive Impairment",[79,80],"18F-PF-06445974","PET Imaging",{"date":33,"type":34},{"date":83,"type":23},"2026-07-16",{"date":85,"type":23},"2030-04-11",{"name":87,"class":88},"National Institute of Mental Health (NIMH)","NIH",{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":24,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":109,"locationsCount":61},"100053254","phase-1-pet-imaging-of-noradrenergic-transmission-in-the-brain-100053254","NCT07686393","PET Imaging of Noradrenergic Transmission in the Brain","* INCLUSION CRITERIA:\n\n  1. Aged 18 years or older.\n  2. Must have undergone a screening assessment under protocol 01-M-0254, The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Participants or 17M0181 Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies.\n  3. Be healthy based on medical history, physical examination, and laboratory testing.\n  4. Able to understand and willingness to provide informed consent.\n  5. Willingness to complete all study procedures including MRI tests.\n  6. Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n  7. Agree to adhere to the lifestyle considerations\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n2. Recent exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits.\n3. Inability to lie flat on camera bed for at least two hours, including claustrophobia and weight greater than the maximum for the scanner (500 lbs).\n4. HIV infection.\n5. Pregnancy or breastfeeding.\n6. Must not have substance use disorder or alcohol use disorder.\n7. Unable to travel to the NIH.\n8. Unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye.\n9. Taking medications reported to have significant binding to alpha-1 adrenoceptors, medications that that alter norepinephrine release, or medications that lower blood pressure including antihypertensives, diuretics, or phosphodiesterase-5(PDE-5) inhibitors (e.g. sildenafil, tadalafil, vardenafil) within five elimination halflives prior to any \\[11C\\]ARMI PET scan.\n10. Known hypersensitivity to quinazoline-class medications (e.g., prazosin), defined as any prior allergic or clinically significant adverse reaction requiring discontinuation or medical evaluation.\n11. Blood donation within 8 weeks (2 months) before study participation, or unwillingness to avoid blood donation for 8 weeks (2 months) after the study.","105 Years",{"count":97,"type":23},40,[26],"Background:\n\nResearchers have developed a new radioactive tracer (11C-ARMI). A tracer is a drug that attaches itself to other chemicals in the body and lights up so that the chemicals can be seen in imaging scans. The new tracer may be able to help them with many diseases, such as Alzheimer s disease and Parkinson s disease. Researchers want to test the new tracer in healthy people.\n\nObjective:\n\nTo test a new tracer (11C-ARMI) during imaging scans of the brain and body in healthy people.\n\nEligibility:\n\nHealthy people aged 18 years and older. They must have been screened under protocols 01-M-0254 or 17M0181.\n\nDesign:\n\nAll participants will have a positron emission tomography (PET)\u002Fcomputed tomography (CT) scan. Before the scan, they will have blood and urine tests and a test of their heart function. The tracer will be given through a tube attached to a needle inserted into a vein in the arm. They will lie on a padded bed that fits inside a doughnut-shaped machine; the machine uses x-rays to create images of the inside of the body.\n\nSome participants will have a PET\u002FCT scan of their whole body. They will need only 1 visit.\n\nSome participants will have a PET\u002FCT scan of only their brain. They will have up to 2 visits. On the second visit, they will have a magnetic resonance imaging (MRI) scan of the brain. For the MRI, they will lie on a table that slides into a cylinder. The MRI uses magnetic fields to create images of the inside of the body.\n\nParticipants will receive a follow-up call to check on their well-being after their PET\u002FCT scans.",[29],[102,103,104,29],"Positron Emission Tomography (PET) Imaging","11C-ARMI","Alpha-1A Adrenoreceptor ( 1A-AR)",{"date":33,"type":34},{"date":83,"type":23},{"date":108,"type":23},"2030-02-20",{"name":87,"class":88},{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":117,"targetDuration":4,"studyType":24,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":61},"100053217","phase-1-glutamatergic-mechanisms-aim2-100053217","NCT05401227","Glutamatergic Mechanisms: Aim2","Glutamatergic Mechanisms of Psychosis and Target Engagement: Aim2","Inclusion Criteria:\n\n1. Age between 18-55 at screen\n2. Medically healthy, as assessed by study physician at screen\n3. Capable of understanding the study procedures and able to provide informed consent\n4. Eligible men and women must agree to use a reliable method of birth control (See section 5.3) during the study. Women who are post-menopausal or otherwise not of childbearing potential are also eligible.\n5. Willing and reliable to participate in XT or placebo phase as an outpatient and\u002For agreeable to participate as an inpatient.\n\nExclusion Criteria:\n\n1. Current or past Axis I psychiatric history (including Substance Use Disorder\u002FAlcohol Use Disorder, with the exception of nicotine use disorder) as assessed at screen\n2. Positive urine toxicology or alcohol at screen\n3. History of recreational ketamine use, recreational PCP use, or an adverse reaction to ketamine. Participants who have participated in prior research ketamine studies will be eligible. Participants can have infusions not more frequently than biweekly, and not more than 1\u002Fmonth on average, therefore participants entering the study will need to wait one month if they had a single infusion and 6 weeks if they have had two closely spaced infusions.\n4. History of first-degree relative with schizophrenia\n5. Pregnancy or breast-feeding. This exclusion criterion applies only to females of child-bearing potential (not surgically sterilized and between menarche and 1 year postmenopausal). Must test negative for pregnancy at the time of screening based on a serum pregnancy test.\n6. History of violence, including any history of using a gun, knife, or other weapon with intent to harm someone, as well as more than one physical fight without a weapon after the age of 18 years old (not including fights that happen during sports competition).\n7. Presence or positive history of significant medical illness at screen, including:\n\n   * Contraindications to XT (urinary retention, moderate or severe hepatic impairment, gastric retention, untreated narrow-angle glaucoma, hypernasality)\n   * renal problems (GFR\\\u003C60)\n   * high blood pressure (defined as supine systolic blood pressure (SBP) \\> 140 or supine diastolic blood pressure (DBP) \\> 90)\n   * low blood pressure (defined as supine SBP \\\u003C 100, DBP \\\u003C 60)\n   * abnormal orthostatic blood pressure (change in mean arterial pressure \\[1\u002F3 systolic + 2\u002F3 diastolic\\] of \\> 20% between supine and standing blood pressures)\n   * clinically significant cardiac illness, as determined by the site physician\n   * clinically significant abnormal screening labs, as determined by the site physician\n8. Participants with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 6 months prior to screening or participants who represent a significant risk of suicide in the opinion of the investigator.\n9. Presence or positive history of neurological illness, including seizures, mental retardation or any other disease\u002Fprocedure\u002Faccident\u002Fintervention associated with significant injury to or malfunction of the central nervous system (CNS), or history of significant head injury.\n10. Any material in the body that is a contraindication for MRI procedures\n11. Currently taking any psychotropic medication, including antidepressant medications, benzodiazepines, antipsychotic medications, mood stabilizers, anti-epileptic medications, and stimulants. We will exclude any participant who requires treatment with any psychotropic medication from one of these classes.",{"count":118,"type":23},120,[26],"In the present study, 120 healthy volunteers (HV) will be randomized to one of three ketamine-induced pharmacoBOLD (phBOLD) arms: low, medium, and high. Within each ketamine arm, participants will be randomized to 4 days of \"study drug\" \\[TS-134 (1st 20 participants) or XT (remaining 100 participants)\\] or placebo in a 5:3 ratio (25 study drug:15 placebo per arm).\n\nDuring the study, each participant will undergo a Screening Period (up to 31 days), a 4-day Treatment Period, and a total of two phBOLD sessions: a first session at Baseline and a second session on Day 4 of the Treatment Period, conducted at least 7 days apart, and a follow up visit.",[29],{"date":33,"type":34},{"date":124,"type":34},"2022-10-15",{"date":126,"type":23},"2029-08",{"name":128,"class":129},"New York State Psychiatric Institute","OTHER",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":17,"sex":137,"minAge":138,"maxAge":20,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":61},"100642016","phase-1-a-study-in-healthy-men-to-test-how-bosentan-influences-the-amount-of-zongertinib-in-the-blood-100642016","NCT07649941","A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the Blood","The Effect of Multiple Oral Doses of Bosentan on the Single Oral Dose Pharmacokinetics of Zongertinib in Healthy Male Subjects (an Open-label, Two-treatment, Two-period Fixed Sequence Trial)","Inclusion criteria :\n\n1. Healthy male trial participant according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood pressure (BP), Pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests\n2. Age of 25 to 55 years (inclusive)\n3. Body mass index (BMI) of 18.5 to 29.9 kg\u002Fm² (inclusive)\n4. Signed and dated written informed consent in accordance with International Council for Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial\n\nExclusion criteria :\n\n1. Any finding in the medical examination (including Blood pressure (BP), Pulse rate (PR) or Electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant by the investigator\n2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate (PR) outside the range of 45 to 90 bpm\n3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance\n4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator\n5. Further exclusion criteria apply.","MALE","25 Years",{"count":140,"type":23},16,[26],"The main objective of this trial is to investigate the effect of a moderate CYP 3A inducer bosentan on the pharmacokinetics of zongertinib.",[29],{"date":145,"type":34},"2026-07-02",{"date":147,"type":34},"2026-06-22",{"date":149,"type":23},"2026-08-19",{"name":151,"class":40},"Boehringer Ingelheim",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":24,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":61},"100642123","phase-1-evaluation-of-11cztp-1-to-image-pde4b-100642123","NCT07625345","Evaluation of [11C]ZTP-1 to Image PDE4B","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet the following criteria:\n\n* Aged 18 years or older.\n* Must have undergone a screening assessment under protocol 01M-0254, \"The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Participants or protocol 17M0181 Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies.\"\n* Be healthy based on medical history, physical examination, and laboratory testing.\n* Able to provide informed consent.\n* Willingness to complete all study procedures including MRI tests.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n* History of neurologic illness or injury with the potential to affect study data interpretation.\n* History of seizures, other than in childhood and related to fever.\n* Recent exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits.\n* Inability to lie flat on camera bed for at least two hours, including claustrophobia and weight greater than the maximum for the scanner (500 lbs).\n* HIV infection.\n* Pregnancy or breastfeeding.\n* Must not have substance use disorder or alcohol use disorder.\n* Unable to travel to the NIH.\n* Unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye.\n* Known hypersensitivity to phosphodiesterase-4 (PDE-4) inhibitors (e.g. apremilast, roflumilast, nerandomilast, crisborole).\n* Taking CYP3A4 inhibitors (e.g. grapefruit juice, clarithromycin, erythromycin, ritonavir); CYP3A4 inducers (e.g. phenobarbital St. John's Wort, rifampicin) or oral contraceptives containing gestodene and ethinyl estradiol.\n\nEXCLUSION OF CHILDREN:\n\nInclusion of children is not appropriate, because this protocol has more than minimal risk from radiation exposure without the possibility of direct benefit.\n\nEXCLUSION OF PREGNANT OR BREASTFEEDING WOMEN:\n\nPregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will perform a pregnancy test at screening and prior to all procedures to ensure participants are not pregnant. The test must be negative in order to continue on the study. In addition to completing a negative urine pregnancy test, on the day of PET scanning prior to PET scan procedures, participants of childbearing potential will undergo a clinical pregnancy screening interview with a licensed independent practitioner to confirm lack of pregnancy.\n\nEXCLUSION OF PARTICIPANTS WHO ARE HIV POSITIVE:\n\nPersons with HIV infection are excluded because HIV infection itself may change cAMP signaling.","101 Years",{"count":97,"type":23},[26],"Background:\n\nPDE4B is a protein in cells that helps turn off certain chemical signals after they ve done their job. It controls inflammation, immune responses, and some brain signaling. Measuring PDE4B levels in the body can help doctors manage a disease or know if a treatment is working. Researchers want to find out if a new tracer (a radioactive substance injected during imaging scans) can help them measure PDE4B in people more effectively.\n\nObjective:\n\nTo test a new tracer (\\[11C\\]ZTP-1) during imaging scans of the brain and body in healthy people.\n\nEligibility:\n\nHealthy people aged 18 and older. They must have been screened under protocols 01M-0254 or 17M0181.\n\nDesign:\n\nParticipants will have either 1 or 2 clinic visits.\n\nDuring their first visit, all participants will have a positron emission tomography (PET)\u002Fcomputed tomography (CT) scan. Prior to the scan, they will have blood and urine tests and a test of their heart function. The study tracer will be given through a tube attached to a needle inserted into a vein in the arm. They will lie on a padded bed that fits inside a doughnut-shaped machine; the machine uses x-rays to create images of the inside of the body.\n\nSome participants will have a PET\u002FCT scan of their whole body. They will need only 1 visit. The visit will last up to about 8 hours.\n\nSome participants will have a PET\u002FCT scan of only their brain. They will also have a magnetic resonance imaging (MRI) scan of the brain. They may need to return for a second visit for the MRI scan.\n\nParticipants will receive a follow-up call to check on their well-being after their PET\u002FCT scans.",[29],[80,164],"11C-ZTP-1",{"date":145,"type":34},{"date":167,"type":23},"2026-07-07",{"date":169,"type":23},"2030-10-03",{"name":87,"class":88},{"id":172,"slug":4,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":17,"sex":18,"minAge":69,"maxAge":70,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":174,"briefSummary":74,"conditions":175,"keywords":176,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":180,"locationsCount":61},"100605983",{"count":72,"type":23},[26],[76,77,29],[79,80],{"date":145,"type":34},{"date":167,"type":23},{"date":85,"type":23},{"name":87,"class":88},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":24,"phases":192,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":61},"100573762","forearm-immobilization-in-t2d-100573762","NCT06750497","Forearm Immobilization in T2D","The Impact of Short-term Forearm Immobilization on Forearm Muscle Glucose and Amino Acid Metabolism of Volunteers With or Without Type 2 Diabetes","FIT2D","Inclusion criteria\n\n* Males and females with or without diagnosed type 2 diabetes\n* Use lifestyle changes, metformin, gliclazide, or a combination thereof as oral glucose-lowering treatments for T2D\n* Aged 18-80 years at the time of signing informed consent\n* 18.5 ≥ BMI ≤ 35 kg·m2\n\nExclusion criteria\n\n* Type 1 or a genetic form of diabetes\n* Any diagnosed cardiovascular (heart) disease or high blood pressure (≥160 mmHg systolic and\u002For ≥100 mmHg diastolic)\n* Chronic use of any prescribed or over-the-counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) that interact with muscle substrate metabolism (e.g. selective serotonin reuptake inhibitors)\n* Consumption of a low-carbohydrate diet\n* Smoking or chewing tobacco\n* Known anaemia\n* Regular use of dietary protein and\u002For amino acid supplements (\\>3 times per week)\n* Currently involved in a structured progressive resistance training program (\\>3 times per week)\n* A personal or family history of thrombosis (clots)\n* Any previous motor disorders or inborn errors in muscle and\u002For lipid metabolism\n* History of kidney disease\n* History of liver disease\n* Pregnant or breastfeeding\n* History of any drug or alcohol abuse in the past two years\n* Claustrophobia\n* Unable to give consent","80 Years",{"count":191,"type":23},26,[193],"NA","The aim of the present study is to assess the impact of short-term forearm immobilization on forearm muscle glucose uptake and amino acid net balance and kinetics in individuals with T2D compared with a control group with normoglycaemia.",[29,196],"Type 2 Diabetes",{"date":145,"type":34},{"date":199,"type":34},"2024-11-21",{"date":201,"type":23},"2027-04-30",{"name":203,"class":129},"Wageningen University",{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":17,"sex":211,"minAge":212,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":24,"phases":216,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":61},"100557461","adding-polyphenol-rich-pulses-to-daily-diet-improves-skin-health-by-reshaping-the-skin-microbiome-100557461","NCT06538415","Adding Polyphenol-rich Pulses to Daily Diet Improves Skin Health by Reshaping the Skin Microbiome","To Determine Whether Adding Polyphenol-rich Pulses to Daily Diet Improves Skin Health by Reshaping the Skin Microbiome and Lipids, and Reducing Oxidative Stress and Inflammation in Women","Inclusion Criteria:\n\n* BMI (18.5-29.9)\n* Body weight ≥110 pounds\n* Fitzpatrick skin type 1,2 and 3.\n\nExclusion Criteria:\n\n* pregnancy\n* breast-feeding\n* impaired fasting glucose\n* frequent alcohol use\n* history of skin cancer\n* sunbathing and the use of tanning bed, intake of vitamin\u002Fmineral supplements\n* habitual high intake of fruits (≥ 2 cups daily)\n* intake of medication that might influence the outcome of the study","FEMALE","45 Years","65 Years",{"count":215,"type":23},50,[193],"Skin health is influenced by the microbiome, lipids, oxidative stress, inflammation, and UV exposure. A 12-week trial with 48 women aged 45-65 will test if polyphenol-rich pulses improve skin health by affecting these factors. Using a white rice control diet, the study will measure skin parameters and analyze correlations with changes in lipids and microbiome, potentially proving the benefits of pulses.",[29],[220,221,222],"Pulse","Women","Skin health",{"date":145,"type":34},{"date":225,"type":34},"2026-05-12",{"date":227,"type":23},"2026-12-31",{"name":229,"class":129},"University of Florida",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":237,"targetDuration":4,"studyType":24,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":245,"leadSponsor":247,"locationsCount":61},"100641754","phase-1-a-clinical-study-of-mk-8527-in-healthy-participants-mk-8527-021-100641754","NCT07661108","A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)","An Open-label, Phase 1 Study to Individually Characterize the Food Effect, the Drug-Drug Interaction Effect of OAT Inhibition, and the Drug-Drug Interaction Effect of P-glycoprotein Inhibition on the Pharmacokinetics of MK-8527 in Healthy Adult Participants","Inclusion Criteria:\n\n* Be in good health\n* Has a body mass index (BMI) between 18 and 32 kg\u002Fm\\^2, inclusive\n\nExclusion Criteria:\n\n* Has an estimated glomerular filtration rate (eGFR) ≤90 mL\u002Fmin\u002F1.73 m\\^2\n* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases\n* Has a history of stomach or intestinal surgery or resection that would potentially alter absorption and\u002For excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed)\n* Has a history of cancer (malignancy)\n* Is taking any medication that contains emtricitabine (FTC) or lamivudine (3TC)",{"count":238,"type":23},44,[26],"Researchers are studying a medicine called MK-8527 to learn how it behaves in the body of healthy adults.\n\nThe goal of this study is to learn about the effect of MK-8527 when it is taken with food or with other medicines. Researchers also want to learn about the safety of MK-8527 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.",[29],"2026-06-30",{"date":145,"type":34},{"date":242,"type":34},{"date":246,"type":23},"2026-10-09",{"name":39,"class":40},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":258,"conditions":259,"keywords":263,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":61},"100645066","pomegranate-dietary-supplements-in-aud-and-ald-100645066","NCT07678567","Pomegranate Dietary Supplements in AUD and ALD","Supplementation of Pomegranate Dietary Supplements and Characterization of Urolithin Metabotypes in Patients With Alcohol Use Disorder (AUD) and Alcohol-associated Liver Disease (ALD)","Healthy Group:\n\nInclusion: Healthy individuals, Exclusion: AUD, ALD, AC, and inflammatory conditions,\n\nAlcohol Use Disorder Group:\n\nInclusion: AUD diagnosis Exclusion: alcohol-associated systemic conditions\n\nAlcohol-associated liver disease Group:\n\nInclusion: early-stage ALD comorbid with AUD Exclusion: Only AUD or AUD with AC\n\nAlcohol-associated cirrhosis Inclusion: AC with AUD Exclusion: AUD, and early stage ALD, as well as determined by the study cohort criteria",{"count":256,"type":23},144,"OBSERVATIONAL","The goal of this project is to determine an individual's ability to generate active gut microbial metabolites called urolithins upon consumption of pomegranate dietary supplements. Recent publications have reported that urolithins are the major active metabolites responsible for the beneficial effects of eating pomegranates, berries, or walnuts. However, the production of urolithins from the parent compound ellagic acid (EA) is dependent upon the presence of certain bacteria in the human gut. In this trial, we propose to investigate variations in gut microbiota and their capacity to metabolize pomegranate dietary supplements (PDS) into active urolithins. We will measure the levels of urolithins in blood as well as inflammatory cytokines in plasma samples upon consumption of PDS.",[260,261,262,29],"Alcohol Use Disorder","Alcohol-associated Liver Disease","Alcoholic Cirrhosis",[264],"Pomeragranate, AUD, ALD",{"date":145,"type":34},{"date":267,"type":23},"2027-01-01",{"date":269,"type":23},"2032-12-31",{"name":271,"class":129},"University of Louisville",{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":17,"sex":18,"minAge":138,"maxAge":69,"enrollmentInfo":279,"targetDuration":4,"studyType":24,"phases":281,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":294,"leadSponsor":296,"locationsCount":61},"100632297","phase-2-stress-buffering-and-sleep-disturbance-resilient-effects-of-a-dual-bifidobacterium-longum-combination-under-short-term-travel-100632297","NCT07511855","Stress-buffering and Sleep Disturbance-resilient Effects of a Dual Bifidobacterium Longum Combination Under Short-term Travel","Stress-buffering and Sleep Disturbance-resilient Effects of a Dual Bifidobacterium Longum Combination Under Short-term Travel: A Randomized, Double-blind, Placebo-controlled Study","Inclusion Criteria:\n\n* Willing to participate in this study and able to provide written informed consent before any study procedures are initiated.\n* Able and willing to comply with all study procedures as required by the protocol, including continuous wearable device use, saliva and stool sample collection, and completion of questionnaire assessments.\n* Willing to accept randomization and group allocation as determined by the study protocol.\n\nExclusion Criteria:\n\n* Known use of antibiotics or systemic corticosteroids within 4 weeks prior to enrollment.\n* Use of probiotic supplements within 4 weeks prior to enrollment.\n* Planned use of any probiotic supplements during the study period.\n* Known history or current presence of major endocrine disorders, active inflammatory bowel disease or other severe gastrointestinal diseases, or severe sleep disorders requiring treatment adjustment.\n* Pregnant or intend to get pregnant, or lactating women.\n* Known allergy to any probiotic products.\n* Participation in any other clinical interventional study involving drugs, dietary supplements, probiotics, or prebiotics within the past three months.\n* Or those who, according to the researcher's judgment, may have inadequate adherence or are unable to complete the study protocol.",{"count":280,"type":23},60,[282],"PHASE2","This study aims to evaluate the effects of a dual Bifidobacterium longum probiotic formulation (dipro-O and dipro-X) on sleep quality, stress responses, and gut microbiota stability in healthy adults during short-term travel. Using a randomized, double-blind, placebo-controlled design, the study investigates whether probiotic supplementation can enhance sleep resilience, buffer stress, and modulate microbiome and physiological responses under travel-related environmental changes.",[29],[286,287,288,289,290],"probiotic","Bifidobacterium","short term travel","sleep","gut microbiota","2026-06-29",{"date":145,"type":34},{"date":57,"type":23},{"date":295,"type":23},"2027-05-31",{"name":297,"class":129},"Min-Tze LIONG",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":17,"sex":18,"minAge":306,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":24,"phases":310,"briefSummary":311,"conditions":312,"keywords":314,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":325,"locationsCount":61},"100645211","app-based-motor-skills-intervention-in-primary-school-and-home-settings-100645211","NCT07679633","App-based Motor Skills Intervention in Primary School and Home Settings","DigiKids C-RCT: App-based Motor Skills Intervention in Primary School and Home Settings","DigiKids RCT","Inclusion Criteria:\n\n* Children enrolled in the first grade of primary school\n* Sufficient Finnish language proficiency\n* Written informed consent from the guardian and written assent from the child\n\nExclusion Criteria:\n\n* Age under 6 or over 8 years\n* Medical or physical conditions preventing participation in the assessments (including severe musculoskeletal complaints or concussions within the preceding 3 months)\n* Refusal to participate in baseline assessments","6 Years","8 Years",{"count":309,"type":23},314,[193],"The objective of this trial is to evaluate the effectiveness of a mobile app-based motor skills intervention (DigiKids RCT) on motor competence, physical activity, and perceived motor competence compared with standard school practices in primary school children. In addition, the study will examine other factors such as child-specific and family-related factors that might influence the findings.",[29,313],"Motor Activity",[315,316,317,318,319],"Physical Activity","Mobile Applications","Child","Behavior","Motor Skills","2026-06-28",{"date":57,"type":34},{"date":323,"type":23},"2026-08-10",{"date":295,"type":23},{"name":326,"class":129},"Tampere University",{"id":328,"slug":4,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":17,"sex":18,"minAge":48,"maxAge":20,"enrollmentInfo":329,"targetDuration":4,"studyType":24,"phases":330,"briefSummary":52,"conditions":331,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":337,"locationsCount":61},"100638851",{"count":50,"type":23},[26],[29],"2026-06-26",{"date":242,"type":34},{"date":335,"type":23},"2026-07-06",{"date":59,"type":23},{"name":39,"class":40},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":24,"phases":348,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":357,"leadSponsor":359,"locationsCount":4},"100644184","evaluation-of-three-neuromuscular-electrical-stimulation-foot-pad-programmes-on-lower-limb-haemodynamics-in-healthy-adults-100644184","NCT07666828","Evaluation of Three Neuromuscular Electrical Stimulation Foot Pad Programmes on Lower Limb Haemodynamics in Healthy Adults","Evaluation of Lower Limb Haemodynamics Using Three (TRI) Neuromuscular Electrical Stimulation Foot Pad Programmes: A Crossover (X) Randomised Controlled Study in Healthy (HE) Adults","TRI-HEX","Inclusion Criteria:\n\n* Healthy\n* Age 18 or over\n* Ability to communicate in English and provide informed consent\n\nExclusion Criteria:\n\n* Lack of capacity to provide informed consent\n* Electronic implanted device (e.g. cardiac pacemaker)\n* Pregnancy or intending to become pregnant during the study period\n* Currently being treated for or have symptoms of an existing deep vein thrombosis (DVT)\n* Diagnosis of vascular disease or disorder\n* Terminal illness\n* Neurological disorders (e.g. epilepsy)\n* Musculoskeletal injury\u002Fdisorders (e.g. recent injury or surgery)\n* Skin conditions (e.g. eczema or open wounds near plantar surface of the foot)\n* Cardiovascular conditions (e.g. arrhythmia or uncontrolled hypertension)\n* Diabetes mellitus with neuropathy.",{"count":347,"type":23},24,[193],"The goal of this clinical investigation is to evaluate the performance of three neuromuscular electrical stimulation (NMES) foot pad programmes in healthy adults. It will also learn about how well the NMES programmes are tolerated.\n\nThe main questions it aims to answer are:\n\n* Do two newly-developed NMES programmes ('P1' and 'PM7') increase lower limb blood flow more than the existing 'Medic' NMES programme during use?\n* How do the programmes compare in terms of user discomfort and muscle oxygenation during use?\n\nResearchers will compare the P1 and PM7 programmes with the existing Medic programme to determine whether the new programmes produce greater improvements in lower limb haemodynamics during device use.\n\nParticipants will:\n\n* Attend four study visits at a single research site.\n* Complete 1 familiarisation visit and 3 testing visits, with 12 hours to 7 days between visits.\n* Use all three NMES programmes once in a randomised order.\n* Receive 30 minutes of NMES during each testing visit.\n* Undergo blood flow and muscle oxygenation measurements during each test.\n* Complete questionnaires about discomfort and their experience using the device.",[29],[352,29,353],"Neuromuscular Electrical Stimulation","Blood flow","2026-06-25",{"date":291,"type":34},{"date":335,"type":23},{"date":358,"type":23},"2027-01",{"name":360,"class":40},"Joey Porter",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":368,"targetDuration":4,"studyType":24,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":374,"leadSponsor":376,"locationsCount":61},"100645189","phase-1-a-single-and-multiple-ascending-dose-escalation-and-food-effect-study-of-qx-4533-in-healthy-participants-100645189","NCT07678463","A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy Participants","A Three-part, Phase 1, Single and Multiple Ascending Dose Escalation and Food Effect Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of QX-4533","Inclusion Criteria:\n\n* Male or female between 18 and 55 years of age (inclusive) at screening.\n* Understands the study procedures and is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Willing and able to comply with this protocol and be available for the entire duration of the study.\n* In good general health, determined by no clinically significant findings in the opinion of the Investigator from medical history, physical examination, 12-lead electrocardiogram (ECG), clinical laboratory findings, and vital signs at screening and Day -1.\n* Has body mass index of 18 to 32 kilograms per meter square (kg\u002Fm\\^2) inclusive.\n\nExclusion Criteria:\n\n* History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease according to the Investigator.\n* History of any Gastrointestinal (GI) procedures (e.g., bariatric surgery) that could impair gastrointestinal absorption.\n* History of any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the participant.\n* Clinically significant abnormalities on pre-study clinical examination or laboratory safety tests. Laboratory safety assessments (e.g., serum chemistry, hematology, coagulation) will be performed at screening and on Day -1 (if screening is prior to Day -1) to confirm eligibility.\n* Treatment with a live (attenuated) vaccine within 8 weeks before the screening visit.\n* Positive hepatitis B surface antigen, human immunodeficiency virus antibody, or hepatitis C antibody at the screening visit.\n* Use of any prescription within 14 days prior to study treatment administration or use of any over-the-counter medications including food supplements and herbal medications (e.g., St. John's wort), except for contraceptive medications and as needed (pro re nata) paracetamol (not exceeding 2 g\u002Fday) within 7 days prior to study treatment administration.\n* Participant has participated in another clinical study within the last 4 weeks or within 5 half-lives of the prior study drug, whichever is longer.\n* Participants that currently use (including \"recreational use\") any illicit drugs or have a history of drug abuse in the last 2 years.",{"count":72,"type":23},[26],"The primary purpose of this study is to evaluate the safety and tolerability of QX-4533 following oral administration of single and multiple ascending doses in healthy participants.",[29],{"date":57,"type":34},{"date":145,"type":23},{"date":375,"type":23},"2027-01-31",{"name":377,"class":40},"QuantX Biosciences, Inc.",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":24,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":61},"100644945","low-carbohydrate-diet-and-low-density-lipoprotein---cholesterol-ldl-c-interindividual-variability-100644945","NCT07675603","Low-carbohydrate Diet and Low-Density Lipoprotein - Cholesterol (LDL-c) Interindividual Variability","Exploring True Interindividual Heterogeneity of Cardiovascular Disease (CVD) Risk Factors in Response to Low-carbohydrate Diets Using a Replicate Crossover Randomised Controlled Trial","REPETO","Inclusion Criteria:\n\n* Age: \\>18 years\n* Body mass index: 18.5-35 kg·m-2\n* Low-Density Lipoprotein-cholesterol \\\u003C4.9 mmol\u002FL\n* Non-fasting triglycerides \\\u003C2.3 mmol\u002FL\n\nExclusion Criteria:\n\n* weight instability (\\>5% change in body mass within last 3 months)\n* smoker\n* diagnosis of hypercholesterolaemia or any other lipid-related disease\n* diagnosis of diabetes\n* diagnosis of atherosclerotic cardiovascular disease\n* elevated fasting glucose (\\>5.4 mmol\u002FL)\n* dietary intolerances or allergies or to other study procedures\n* diagnosis of gastrointestinal disorders\n* any other condition\u002Fmedication that could introduce bias to the study\n* already following a ketogenic diet\n* not willing to follow a ketogenic diet\n* unable to understand English language",{"count":387,"type":23},20,[193],"Ketogenic diets are very low-carbohydrate diets that increase hepatic production of ketone bodies, which have several effects as substrates and signals. Ketogenic diets are used to manage some conditions (e.g., drug-resistant epilepsy), and their potential for managing many other conditions (e.g., cancer) is being actively explored. Indeed, the British Dietetic Association acknowledge the potential for ketogenic diets to improve glycaemic control to a greater extent than some other diets in people with type 2 diabetes. A lower fasting glucose is also relevant to future mortality in people without diabetes. Ketogenic diets are popular in the general population, with up to 15% of the UK following a low-carbohydrate diet. There is, therefore, great interest in ketogenic diets amongst people with and without health conditions. However, although the diet shows promising results in improving blood sugar levels, it has also shown to increase low-density lipoprotein-cholesterol (LDL-c) in some individuals, which has been linked to increased cardiovascular health risks. The aim of this project is to find the potential for personalised use of (or guidance to avoid) ketogenic diets for cardiovascular disease risk. To do that the investigators will ask participants to replicate 24 hours of a ketogenic diet and a control diet thrice each. This will allow the investigators to find variability between responses and have a better idea of individuals who could benefit (or not) from following the ketogenic diet.",[29],{"date":242,"type":34},{"date":393,"type":34},"2026-02-05",{"date":395,"type":23},"2027-03",{"name":397,"class":129},"University of Bath",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":17,"sex":18,"minAge":405,"maxAge":406,"enrollmentInfo":407,"targetDuration":4,"studyType":24,"phases":409,"briefSummary":410,"conditions":411,"keywords":413,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":423,"locationsCount":4},"100645249","influence-of-a-parent-mediated-mhealth-motor-skill-intervention-on-preschool-childrens-motor-skills-and-cognitive-function-100645249","NCT07680075","Influence of a Parent-mediated mHealth Motor Skill Intervention on Preschool Children's Motor Skills and Cognitive Function","COSMIC","Inclusion Criteria:\n\n* Children will be included if they are 3-5 years of age at the time of enrollment and their accompanying parents (Age 18 or above).\n\nExclusion Criteria:\n\n* Child exclusion criteria: Physical or cognitive disability that parent feels will preclude participation in activity breaks or assessments (physical activity or gross motor skill activities).\n\nParent exclusion criteria: No parental access to a smartphone, tablet or computer; physical limitation that impairs modeling of activities; parent cannot read and understand English.","3 Years","5 Years",{"count":408,"type":23},35,[193],"The proposed study uses a mHealth application \"app\" to help parents teach their preschool-age child motor skill (FMS) activities in the home environment. This app guides families to participate in 10-min activity breaks, 7 days\u002Fweek for 12 weeks and the app includes weekly instructional lessons, peer modeling videos, behavioral scaffolding, and structured activities. This study builds on prior work by assessing whether improvements in FMS generalize to cognitive domains, including executive function skills such as working memory, attention, and inhibitory control. By examining both motor and cognitive outcomes, the project will provide essential evidence on whether enhanced FMS uniquely contributes to cognitive development. Based on findings from the proposed study, there may be a need to develop additional modules that address diverse needs of children or that contribute to broader, multifaceted improvement in both motor competence and cognitive function. Findings will inform the potential of technology-based motor skill interventions to support broader aspects of child development in diverse populations, guiding future practice and policy in education, health, and early intervention.",[412,319,29],"Executive Function",[414,415,416,417,418],"mHealth","preschool","motor skill","executive function","parent-mediated",{"date":145,"type":34},{"date":242,"type":23},{"date":422,"type":23},"2027-06-30",{"name":424,"class":129},"University of Tennessee",{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":432,"enrollmentInfo":433,"targetDuration":4,"studyType":24,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":444},"100605929","phase-1-a-study-of-v118e-in-healthy-participants-v118e-003-100605929","NCT07168915","A Study of V118E in Healthy Participants (V118E-003)","A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V118 Formulation E in Healthy Adults","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n\\- Is in good health before randomization\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination\n* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases","49 Years",{"count":434,"type":23},126,[26],"Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria.\n\nPREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria.\n\nThe goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.",[29],{"date":291,"type":34},{"date":440,"type":34},"2025-10-08",{"date":442,"type":23},"2027-11-12",{"name":39,"class":40},4,{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":24,"phases":454,"briefSummary":456,"conditions":457,"keywords":458,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":61},"100601440","early-phase-1-positron-emission-tomography-pet-contrast-agent-kinetics-and-safety-18f-fluoromannitol-100601440","NCT07110519","Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol","Inclusion Criteria:\n\nHealthy volunteers, 18-75 years of age.\n\n* Female participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.\n* Informed consent signed by participant according to the guidelines of the institutional review board.\n\nExclusion Criteria:\n\nInitial Eligibility Exclusion Criteria (Entry to Screening Phase -\n\n* Participant currently has a fever or other symptoms concerning for an active infection or is currently undergoing treatment for an active infection.\n* Participant has been diagnosed and\u002For treated for a known or suspected bacterial infection within the past 60 days.\n* Participant has known disease of the lung, liver, kidneys, gastrointestinal tract, bones\u002Fjoints, or known immune suppression or autoimmune disease that is likely to have active inflammation (examples to exclude: Crohn's disease, COPD; example to i include: well controlled asthma)\n* Participant has prosthetic or indwelling device(s) currently or has had one in the past 60 days.\n* Participant is pregnant or breastfeeding.\n* Use of drugs known to have interaction or be affected by mannitol within 60 days of enrollment.\n* Participant has any condition that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol, including being unable to tolerate the PET scan procedures.\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.\n* Participant is currently participating in another study subject to an IND.\n\nFinal Eligibility Exclusion Criteria (Entry to Study):\n\nAt the time of the Final Eligibility Determination (Imaging Study Visit 1):\n\n* Participant no longer meets one or more of the Inclusion Criteria\n* Participant now fails one or more of the Initial Eligibility Exclusion Criteria\n* Estimated glomerular filtration rate is \\\u003C 45 ml\u002Fminute\u002F1.73m2\n* Positive pregnancy test (females only)\n* One or more of the results from laboratory (hematology, chemistries, inflammatory markers), vital signs, or ECG specified in the schedule of evaluations is outside the normal institutional range AND is clinically significant in the opinion of the investigator.\n\nRe-screening will not be allowed unless the Investigator considers the cause of the initial screen failure to be of an acute and\u002For completely reversible nature.","75 Years",{"count":453,"type":23},10,[455],"EARLY_PHASE1","This is a Phase 0 interventional, non-therapeutic study investigating the biodistribution and safety of \\[18F\\]-fluoromannitol as a radiotracer (a substance used to help detect disease or infection) in Positron Emission Tomography (PET) scans.\n\nThe primary objective of this study is to generate safety data in healthy adult human volunteers. In the future, this tracer may help to determine if a medical problem is infectious in people who have Sickle Cell Disease, cancer or other conditions that impact the immune system, or with people who have joint implants.\n\nPrimary Objective\n\n\\- Generate safety data, biodistribution and perform human organ dosimetry for \\[18F\\]- fluoromannitol as a novel PET tracer.\n\nParticipants will be recruited primarily from St. Jude Children's Research Hospital employees and SJLIFE participants, and from the broader Memphis community if needed.",[29],[29,459,460,461],"Adult","Age 18-75 years","Volunteer",{"date":332,"type":34},{"date":464,"type":34},"2025-09-17",{"date":466,"type":23},"2027-05",{"name":468,"class":129},"St. Jude Children's Research Hospital",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":17,"sex":18,"minAge":477,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":24,"phases":480,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":486,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":61},"100585012","increasing-physical-activity-through-social-support-and-stress-resilience-100585012","NCT06896825","Increasing Physical Activity Through Social Support and Stress Resilience","Increasing Physical Activity Through Social Support and Stress Resilience (I-PASS) Among Older Adults Living Alone With SCD to Lower ADRD Risk","I-PASS","Inclusion Criteria:\n\n* Aged 60 years or older\n* Living alone and community dwelling\n* Engaging in 60 minutes or less per week of self-reported moderate-to-vigorous physical activity at screening (based on Exercise Vital Sign Questionnaire)\n* Self-reported decline in cognitive functioning\n* Self-reported ownership of\u002Fwillingness to use a smartphone with an iOS or Android operating system (necessary for participants to track their activity using a wearable activity monitor).\n* Able to read and speak in English. We hope to offer the intervention in Spanish in the future; however, currently, the study materials are only available in English, and participation will require ability to read and respond to study materials.\n\nExclusion Criteria:\n\n* Endorsing an item on the Physical Activity Readiness Questionnaire (PAR-Q), unless a physician's note is provided\n* Resting blood pressure greater than 200\u002F110 mmHG as assessed at the baseline study assessment (unless a physician's note is provided)\n* Plans to relocate out of metropolitan Phoenix, Arizona area in the next 6 months\n* Participation in another physical activity, nutrition or weight loss program at time of screening or at any time during the intervention\n* Individuals with mild cognitive impairment (MCI), as determined by either a self-report of receiving a diagnosis of MCI from a health care provider or as assessed by the Telephone-Montreal Cognitive Assessment (T-MoCA) at the Baseline Session. A score \\\u003C 18 is an exclusion criterion.\n* Individuals with neurodegenerative (e.g., dementia), developmental (e.g., autism), neurologic (e.g., Parkinson's, epilepsy), or major psychiatric (e.g., bipolar, schizophrenia) diagnoses\n* Being previously prescribed one of the 5 approved Alzheimer's medications, including: Donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Razadyne), Memantine (Namenda), Memantine + Donepezil (Namzaric)\n* Score of 9 or higher on the 15-item Geriatric Depression Scale (GDS) at the Baseline Session \\[scores of 9 and higher are indicative of moderate to severe depression\\]\n* History of stroke\n* Incarcerated individuals (i.e., Prisoners)","60 Years",{"count":479,"type":23},86,[193],"The goal of this clinical trial is to learn the effects of technology enhancements when combined with basic education, goal-setting, and self-monitoring to increase physical activity among older adults living alone, experiencing subjective cognitive decline, and currently engaging minimal physical activity (60 minutes or less of moderate to vigorous physical activity). Further, we will examine key psychosocial mechanisms believed to contribute to successful promotion of physical activity, which include social support and stress resilience.\n\nThe primary questions are to determine whether\n\n* the tech-enhanced condition lead to greater physical activity over time?\n* the tech-enhanced condition lead to social support and stress resilience over time?\n* social support and stress resilience mediate the relationship between the study condition and physical activity?\n\nAll participants will engage in self-monitoring of physical activity, will receive weekly text reminders of their physical activity goals for the week, and will receive basic education about the importance of physical activity, social support, and stress resilience for cognitive, physical, and psychological health. Participants in the tech-enhanced condition will also receive access to a study-specific website and virtual coaching to reinforce the information presented. Researchers will then compare the tech-enhanced condition to the basic education condition to determine the benefits of technology to deliver the intervention materials in order to increase physical activity, social support, and stress resilience.\n\nParticipants will:\n\n* Use a Garmin wearable device to monitor their physical activity\n* Be randomly assigned to a basic education condition or tech-enhanced condition\n* Set achievable goals for weekly physical activity, with incremental increases to achieve 7000 average daily steps by the end of the study\n* Respond to surveys to monitor their social support, stress resilience, quality of life, and depression.\n\nThe sample has several risk factors for Alzheimer's disease and related dementias: low physical activity, social isolation risk via living alone, and subjective cognitive impairment. Therefore, a long-term goal includes the determination of the intervention's effectiveness at increasing physical activity, social support, and stress resilience to reduce risk for developing dementia.",[29,483,484,485],"Subjective Cognitive Decline (SCD)","Sedentary Behavior","Social Isolation in Older Adults",{"date":291,"type":34},{"date":488,"type":34},"2025-06-23",{"date":490,"type":23},"2027-04",{"name":492,"class":129},"Arizona State University",{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":17,"sex":18,"minAge":501,"maxAge":306,"enrollmentInfo":502,"targetDuration":4,"studyType":24,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":61},"100509056","the-early-childhood-friendship-project---phase-3-100509056","NCT05908461","The Early Childhood Friendship Project - Phase 3","The Early Childhood Friendship Project: Testing Key Mechanisms and the Moderating Role of Physiological Reactivity","ECFP-3","Inclusion Criteria:\n\n* A child is eligible if attending one of the participating child care centers in the greater Buffalo region of Western New York and planning to enter kindergarten in the fall.\n\nExclusion Criteria:\n\n* None","4 Years",{"count":503,"type":23},600,[193],"The purpose of this study is to assess the impact of the Early Childhood Friendship Project (ECFP) on changes in aggression\u002Fpeer victimization subtypes, prosocial behavior, and social and academic competence with a teacher-implemented (with coaching) version of the program. Further, investigators will examine whether changes in executive functioning, emotion regulation, and hostile attribution biases indirectly account for the program effects. Investigators will test if physiological reactivity (skin conductance and respiratory sinus arrhythmia) serves as moderators of intervention effects. Data will be collected from 600 children (30 randomly assigned preschool classrooms) diverse in socioeconomic status and race\u002Fethnicity. Investigators will use multiple methods (school-based observations, direct academic assessments, child interviews, physiological reactivity using two tasks, observer, caregiver, and teacher reports) to assess the efficacy of the program, hypothesized mechanisms, and role of physiology as a moderator of intervention effects. The duration of the effects will be tested at both 4 month and 12-month follow-up and will thus demonstrate the impact the program has on children's school readiness and transition to kindergarten. It is expected that preschool children randomly assigned to the ECFP intervention relative to the control condition will show significant and moderate reductions in physical and relational aggression\u002Fvictimization at post-test and follow-up; the ECFP intervention group will also show increases in prosocial behavior, social competence, and academic competence, relative to the control group at post-test and follow-up (4-months at the end of preschool and 12 months after transitioning to kindergarten). Additionally, it is hypothesized that changes in executive functioning, emotion regulation, and hostile attribution biases will mediate treatment effects from baseline to respective follow-ups. It is anticipated that these hypothesis will be moderated by gender such that effects will be stronger for girls relative to boys. Finally, it is hypothesized that physiological reactivity will act as a moderator of intervention effects and of the executive functioning, emotion regulation, and hostile attribution biases mechanisms.",[29],{"date":242,"type":34},{"date":509,"type":34},"2023-08-16",{"date":511,"type":23},"2027-04-16",{"name":513,"class":129},"State University of New York at Buffalo",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":521,"targetDuration":4,"studyType":24,"phases":523,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":4},"100644870","phase-1-a-clinical-trial-of-mk-1403-in-healthy-participants-mk-1403-007-100644870","NCT07677163","A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)","A Clinical Study to Evaluate the Relative Bioavailability of MK-1403 Formulations Administered to Healthy Adult Participants","Inclusion Criteria:\n\n* Is in good health\n* Has a body mass index (BMI) ≥ 18 and ≤ 32 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Has history of cancer (malignancy)\n* Has a history of significant multiple and\u002For severe allergies",{"count":522,"type":23},15,[26],"The purpose of this trial is to learn about a trial medicine called MK-1403. Researchers designed MK-1403 to treat a type of heart and blood vessel disease called atherosclerotic cardiovascular disease (ASCVD).\n\nBefore giving a trial medicine to people with a health condition, researchers first do clinical trials in healthy people. This trial will help researchers learn about the safety of MK-1403 and if participants tolerate it. Tolerate means participants receive the trial medicine and they do not need to stop taking it due to health problems. The trial will also measure what happens to MK 1403 in a healthy person's body over time.",[29],"2026-06-24",{"date":242,"type":34},{"date":529,"type":23},"2026-07-29",{"date":531,"type":23},"2026-09-22",{"name":39,"class":40},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":539,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":541,"conditions":542,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":548,"locationsCount":61},"100487846","breathing--blood-pressure-100487846","NCT05632406","Breathing & Blood Pressure","Inclusion Criteria:\n\n• Body mass index values of ≤40 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Not weight stable (\\\u003C5% change in body mass over the past six months)\n* Overt cardiovascular, neurological, renal, liver, and\u002For metabolic illness (e.g., diabetes mellitus)\n* Current, or history of uncontrolled, Stage 2 hypertension (blood pressure \\>140 \u002F 90 mmHg; anti-hypertensive medications are permitted)\n* Diagnosed obstructive sleep apnea\n* Previous bariatric surgery\n* Diagnosis or signs (e.g., values below the lower limit of normal) of overt airway disease(s)\n* Current or recent (regular use within the past 6 months) use of tobacco or nicotine products (e.g., cigarettes, vaping)\n* Per the POWERbreathe® company:\n* Patients who have undergone recent abdominal surgery and those with abdominal hernia.\n* Asthma patients who have a very low symptom perception and suffer from frequent, severe exacerbations or with an abnormally low perception of dyspnoea.\n* If a patient is suffering from a ruptured eardrum or any other condition of the ear.\n* Patients with marked elevated left ventricular end-diastolic volume and pressure.\n* Patients with worsening heart failure signs and symptoms after a respiratory\u002Finspiratory muscle training (IMT) session\n* If you are suffering from a cold, sinusitis, or respiratory tract infection, we advise that you do not use your POWERbreathe IMT device.\n* Individuals who are not yet adults (infants, children, teenagers)\n* Pregnant (self-reported and urine pregnancy test conducted), lactating (self-reported), or post-menopausal (self-reported) females\n* Prisoners",{"count":540,"type":23},80,"The purpose of this study is to determine the effect of obesity on cardiovascular responses during various breathing maneuvers.",[29,543],"Overweight and Obesity",{"date":332,"type":34},{"date":546,"type":34},"2023-10-25",{"date":422,"type":23},{"name":549,"class":129},"Florida State University"]